The FDA used its 2027 budget proposal to outline steps intended to shorten the time to first-in-human trials, with an optional, risk-based Investigational New Drug pathway for certain candidates. The proposed framework is aimed at easing early development burden in the U.S. for programs with preclinical data that can be confirmed without animal testing. The proposal is positioned as a response to shifts in early-stage development activity toward other markets, including China. If implemented through congressional action, the FDA said the pathway could create an accelerated route to Phase 1 in the U.S. while lowering development costs. Separate coverage also framed the budget as including a push toward making a priority voucher program permanent and adding new pathways meant to boost domestic clinical trial initiation and capacity. The net regulatory message is a more proactive stance, but timelines for adoption remain dependent on legislative approval.